---
title: SMARCA2 Small Molecule Drug Discovery Case Study Series
---

![SMARCA2 Header](https://info.xtalpi.com/hubfs/SMARCA2%20Header.png "SMARCA2 Header")

Case Study: How the XtalPi Team Discovered a Selective, Novel Lead Series for Key Cancer Target SMARCA2

Mutations in SMARCA4 drive cancer dependency on SMARCA2, making SMARCA2 a key therapeutic target. XtalPi leveraged AI-powered discovery platform and Cryo-EM technology to overcome challenges in developing selective SMARCA2 inhibitors.

 

Our Key Results:

- Discovered a lead series with **20-fold selectivity** for SMARCA2 over SMARCA4.
- Identified a unique SMARCA2 binding pocket at **2.9 Å resolution** using Cryo-EM.
- Achieved **100% compound synthesis success** through predictive models.

<https://www.linkedin.com/company/xtalpi/> <https://www.xtalpi.com/en> [mailto:bd@xtalpi.com](mailto:bd@xtalpi.com)